(Q37412918)

20 August 2017

1 reference

title

Oral phosphate binders (English)

1 reference

20 August 2017

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

11 March 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

75

1 reference

20 August 2017

issue

9

1 reference

20 August 2017

page(s)

906-914

1 reference

Phosphate is a uremic toxin

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Hypocalcemia, morbidity, and mortality in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

The number, quality, and coverage of randomized controlled trials in nephrology.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Phosphate binders: hold the calcium?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

The mechanism of phosphorus as a cardiovascular risk factor in CKD

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Hidden Sources of Phosphorus in the Typical American Diet: Does it Matter in Nephrology?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Biochemical and hematological changes in low-level aluminum intoxication

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Aluminum as a toxicant

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Frequency of elevated serum aluminum levels in adult dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Dialysis encephalopathy secondary to aluminum toxicity, diagnosed by bone biopsy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Histological, radiological, and biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Vascular calcification in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Arterial calcification after vitamin-D therapy in hyperphosphatemic renal failure.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Calcium alginate versus aluminum hydroxide in patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Calcium requirements: new estimations for men and women by cross-sectional statistical analyses of calcium balance data from metabolic studies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Calcium exposure and removal in chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Calcium-based phosphate binders are appropriate in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

The case against calcium-based phosphate binders

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Magnesium studies in hemodialysis patients before and after treatment with low dialysate magnesium

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Serum magnesium level and arterial calcification in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Systemic lanthanum is excreted in the bile of rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Letter regarding 'Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate'.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Can the risk of gadolinium be extrapolated to lanthanum?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

New developments in the management of hyperphosphatemia in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Dietary magnesium reduction to 25% of nutrient requirement disrupts bone and mineral metabolism in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Magnesium deficiency and osteoporosis: animal and human observations

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Serum magnesium concentration and PTH levels. Is long-term chronic hypermagnesemia a risk factor for adynamic bone disease?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Luminal fructose inhibits rat intestinal sodium-phosphate cotransporter gene expression and phosphate uptake

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

The effect of diet education on the laboratory values and knowledge of hemodialysis patients with hyperphosphatemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Patient empowerment in the management of hyperphosphatemia.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Management of hyperphosphatemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Patient education: an efficient adjuvant therapy for hyperphosphatemia in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Practice recommendations based on low, very low, and missing evidence

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Achieving K/DOQI Laboratory Target Values for Bone and Mineral Metabolism: An Uphill Battle

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Surrogate Markers in Clinical Studies: Problems Solved or Created?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Phosphate binder choice in dialysis patients: a call for evidence-based rather than marketing-based clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.60

7 January 2021

Identifiers

DOI

10.1038/KI.2009.60

1 reference

20 August 2017

1 reference